Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Karuna Therapeutics, Inc. KRTX
$227.54
-$0.26 (-0.11%)
На 18:01, 12 мая 2023
+6.79%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
8500911320.00000000
-
week52high
278.25
-
week52low
92.26
-
Revenue
10637000
-
P/E TTM
-28
-
Beta
1.12094300
-
EPS
-9.33000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:00
Описание компании
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 15 авг 2022 г. |
| RBC Capital | Outperform | Outperform | 12 авг 2022 г. |
| Guggenheim | Buy | Buy | 12 авг 2022 г. |
| Wells Fargo | Overweight | Overweight | 10 авг 2022 г. |
| Mizuho | Buy | Buy | 09 авг 2022 г. |
| Stifel | Buy | Buy | 13 сент 2022 г. |
| RBC Capital | Outperform | Outperform | 29 сент 2022 г. |
| Loop Capital | Buy | 01 ноя 2022 г. | |
| Wells Fargo | Overweight | Overweight | 04 ноя 2022 г. |
| Piper Sandler | Overweight | 05 янв 2023 г. | |
| HC Wainwright & Co. | Buy | 01 февр 2023 г. | |
| UBS | Neutral | 27 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Ignelzi Troy A. | D | 109726 | 200 | 18 янв 2023 г. |
| Ignelzi Troy A. | D | 21837 | 200 | 18 янв 2023 г. |
| Ignelzi Troy A. | A | 22037 | 200 | 18 янв 2023 г. |
| Ignelzi Troy A. | D | 109926 | 817 | 17 янв 2023 г. |
| Ignelzi Troy A. | D | 21837 | 817 | 17 янв 2023 г. |
| Ignelzi Troy A. | A | 22654 | 817 | 17 янв 2023 г. |
| HEALY JAMES | D | 0 | 6027 | 13 янв 2023 г. |
| HEALY JAMES | A | 6027 | 6027 | 12 янв 2023 г. |
| HEALY JAMES | D | 1772441 | 300000 | 12 янв 2023 г. |
| Brannan Stephen K. | D | 0 | 3473 | 09 янв 2023 г. |
Новостная лента
Karuna Therapeutics, Inc. (KRTX) Q1 2023 Earnings Call Transcript
Seeking Alpha
06 мая 2023 г. в 02:55
Karuna Therapeutics, Inc. (NASDAQ:KRTX ) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Alexis Smith - Senior Director of Investor Relations Bill Meury - President and Chief Executive Officer Troy Ignelzi - Chief Financial Officer Andrew Miller - Founder and Chief Operating Officer Conference Call Participants Paul Matteis - Stifel Nick Lenard - JPMorgan Jason Gerberry - BofA Securities Neena Bitritto-Garg - Citi Laura Chico - Wedbush Securities Jay Olson - Oppenheimer David Amsellem - Piper Sandler Yatin Suneja - Guggenheim Securities Myles Minter - William Blair Jason Butler - JMP Securities Joseph Spak - RBC Capital Markets Rudy Li - SVB Securities Operator Welcome to the Karuna Therapeutics First Quarter 2023 Financial Results Conference Call. All participants are in a listen-only mode.
Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q1
Zacks Investment Research
05 мая 2023 г. в 12:09
Karuna Therapeutics (KRTX) reports encouraging first-quarter 2023 results. The company beats estimates for earnings and sales.
Karuna Therapeutics to Present at Upcoming Investor Conferences
Business Wire
02 мая 2023 г. в 06:30
BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that management will present at the following upcoming investor conferences: BofA Securities 2023 Health Care Conference Date: Wednesday, May 10, 2023 Time: 5:00 p.m. PT (8:00 p.m. ET) 2023 RBC Capital Markets Global Healthcare Conference Date: Wednesday,.
3 Biotech Buyout Targets to Watch
The Motley Fool
29 апр 2023 г. в 08:25
89bio's stock is up more than 21% this year. Karuna Therapeutics says it plans to file an NDA for its lead therapy this year.
Karuna Therapeutics to Announce First Quarter 2023 Financial Results and Provide General Business Update on Thursday, May 4, 2023
Business Wire
20 апр 2023 г. в 06:30
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it will host a live conference call and webcast on Thursday, May 4, 2023 at 8:00 a.m. ET to review first quarter 2023 financial results and provide a general business update.